Neuphoria Therapeutics Inc Net Assets
Neuphoria Therapeutics Inc net assets. Based on the latest financial reports, Neuphoria Therapeutics Inc (NEUP) has net assets worth $24.60 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($28.71 Million) and total liabilities ($4.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Neuphoria Therapeutics Inc (NEUP) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $24.60 Million |
| % of Total Assets | 85.69% |
| Annual Growth Rate | N/A |
| 5-Year Change | 43128.58% |
| 10-Year Change | 79033.92% |
| Growth Volatility | 16360.99 |
Net Assets of Neuphoria Therapeutics Inc (1999–2026)
Net assets of Neuphoria Therapeutics Inc from 1999 to 2026. This chart illustrates how Neuphoria Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Neuphoria Therapeutics Inc to measure how much of total assets are equity-financed.
Annual Net Assets for Neuphoria Therapeutics Inc (1999–2026)
The table below shows the annual net assets of Neuphoria Therapeutics Inc from 1999 to 2026. For live market cap and overall valuation, see market value of Neuphoria Therapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2026-06-30 | $24.60 Billion | +85102.23% |
| 2025-06-30 | $28.87 Million | +65.08% |
| 2024-06-30 | $17.49 Million | +19.37% |
| 2023-06-30 | $14.65 Million | -74.25% |
| 2022-06-30 | $56.91 Million | +59.13% |
| 2021-06-30 | $35.76 Million | +310.39% |
| 2020-06-30 | $8.71 Million | -29.70% |
| 2019-06-30 | $12.39 Million | -0.50% |
| 2018-06-30 | $12.46 Million | -59.93% |
| 2017-06-30 | $31.09 Million | -1.90% |
| 2016-06-30 | $31.69 Million | +29.25% |
| 2015-06-30 | $24.52 Million | -41.90% |
| 2014-06-30 | $42.20 Million | +11.67% |
| 2013-06-30 | $37.79 Million | +42.57% |
| 2012-06-30 | $26.51 Million | -13.59% |
| 2011-06-30 | $30.67 Million | +41.72% |
| 2010-06-30 | $21.64 Million | +43.45% |
| 2009-06-30 | $15.09 Million | -26.75% |
| 2008-06-30 | $20.60 Million | +6.98% |
| 2007-06-30 | $19.25 Million | +137.02% |
| 2006-06-30 | $8.12 Million | -0.25% |
| 2005-06-30 | $8.14 Million | +30.41% |
| 2004-06-30 | $6.24 Million | +38.00% |
| 2003-06-30 | $4.52 Million | -19.54% |
| 2002-06-30 | $5.62 Million | +8.18% |
| 2001-06-30 | $5.20 Million | +72.00% |
| 2000-06-30 | $3.02 Million | +930.72% |
| 1999-06-30 | $-363.81K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neuphoria Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19179801918900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Neuphoria Therapeutics Inc Net Assets Breakdown (June 2026)
Neuphoria Therapeutics Inc net assets breakdown by equity component as of June 2026.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $54.00K | 0.00% |
| Other Comprehensive Income | $-2.06 Billion | -8.39% |
| Other Components | $218.46 Billion | 888.06% |
| Total Equity | $24.60 Billion | 100.00% |
Neuphoria Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Neuphoria Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Locksley Resources Ltd
AU:LKY
|
$16.19 Million |
|
SyntekaBio Inc
KQ:226330
|
$16.19 Million |
|
Alpha Microelectronics
TWO:8024
|
$16.22 Million |
|
Pensonic Holdings Bhd
KLSE:9997
|
$16.22 Million |
|
OURGAME INT.HOL.DL-00005
F:13O
|
$16.17 Million |
|
Baid Finserv Limited
NSE:BAIDFIN
|
$16.16 Million |
|
New Bubbleroom Sweden AB
ST:BBROOM
|
$16.14 Million |
|
Diamyd Medical AB (publ)
ST:DMYD-B
|
$16.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neuphoria Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 28,872,510 to 24,600,022,000, a change of 24,571,149,490 (85102.2%).
- Net loss of 13,451,931 reduced equity.
- New share issuances of 17,915,883 increased equity.
- Other comprehensive income decreased equity by 2,058,847,207.
- Other factors increased equity by 26,625,532,745.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.45 Million | -0.05% |
| Share Issuances | $17.92 Million | +0.07% |
| Other Comprehensive Income | $-2.06 Billion | -8.37% |
| Other Changes | $26.63 Billion | +108.23% |
| Total Change | $- | 85102.23% |
Book Value vs Market Value Analysis
This analysis compares Neuphoria Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-06-30 | $-1.45 | $2.99 | x |
| 2000-06-30 | $2.46 | $2.99 | x |
| 2001-06-30 | $2.19 | $2.99 | x |
| 2002-06-30 | $1.84 | $2.99 | x |
| 2003-06-30 | $1.35 | $2.99 | x |
| 2004-06-30 | $1.54 | $2.99 | x |
| 2005-06-30 | $1.51 | $2.99 | x |
| 2006-06-30 | $0.63 | $2.99 | x |
| 2007-06-30 | $1.28 | $2.99 | x |
| 2008-06-30 | $1.10 | $2.99 | x |
| 2009-06-30 | $0.75 | $2.99 | x |
| 2010-06-30 | $0.86 | $2.99 | x |
| 2011-06-30 | $1.14 | $2.99 | x |
| 2012-06-30 | $0.92 | $2.99 | x |
| 2013-06-30 | $1.21 | $2.99 | x |
| 2014-06-30 | $1.21 | $2.99 | x |
| 2015-06-30 | $0.70 | $2.99 | x |
| 2016-06-30 | $0.83 | $2.99 | x |
| 2017-06-30 | $0.77 | $2.99 | x |
| 2018-06-30 | $0.31 | $2.99 | x |
| 2019-06-30 | $0.29 | $2.99 | x |
| 2020-06-30 | $0.19 | $2.99 | x |
| 2021-06-30 | $0.55 | $2.99 | x |
| 2022-06-30 | $0.50 | $2.99 | x |
| 2023-06-30 | $0.12 | $2.99 | x |
| 2024-06-30 | $0.12 | $2.99 | x |
| 2025-06-30 | $17.79 | $2.99 | x |
| 2026-06-30 | $5596.00 | $2.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neuphoria Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1145.66%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.17x
- Recent ROE (-0.05%) is above the historical average (-43.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 0.00% | 0.00% | 0.00x | 0.00x | $-188.58K |
| 2000 | -28.03% | 0.00% | 0.00x | 1.05x | $-1.15 Million |
| 2001 | -32.19% | -279.37% | 0.11x | 1.06x | $-2.19 Million |
| 2002 | -34.94% | -216.54% | 0.10x | 1.59x | $-2.53 Million |
| 2003 | -67.62% | -441.62% | 0.08x | 1.87x | $-3.51 Million |
| 2004 | -40.02% | -852.13% | 0.03x | 1.68x | $-3.12 Million |
| 2005 | -43.38% | -1204.34% | 0.02x | 1.60x | $-4.35 Million |
| 2006 | -49.30% | -827.28% | 0.03x | 1.80x | $-4.82 Million |
| 2007 | -24.01% | -666.81% | 0.03x | 1.36x | $-6.55 Million |
| 2008 | -22.22% | -424.86% | 0.04x | 1.32x | $-6.64 Million |
| 2009 | -36.71% | -190.07% | 0.15x | 1.32x | $-7.05 Million |
| 2010 | -32.26% | -274.41% | 0.09x | 1.24x | $-9.15 Million |
| 2011 | -32.60% | -293.94% | 0.09x | 1.20x | $-13.07 Million |
| 2012 | -12.11% | -60.04% | 0.17x | 1.20x | $-5.86 Million |
| 2013 | -24.15% | -365.50% | 0.05x | 1.29x | $-12.91 Million |
| 2014 | 7.15% | 16.75% | 0.29x | 1.45x | $-1.20 Million |
| 2015 | -53.02% | -255.68% | 0.10x | 2.16x | $-15.45 Million |
| 2016 | -39.14% | -237.84% | 0.08x | 2.07x | $-15.57 Million |
| 2017 | -16.68% | -19.11% | 0.42x | 2.08x | $-8.30 Million |
| 2018 | -147.93% | -154.30% | 0.25x | 3.84x | $-19.67 Million |
| 2019 | -54.63% | -91.57% | 0.20x | 3.03x | $-8.01 Million |
| 2020 | -56.13% | -15255.18% | 0.00x | 2.72x | $-5.76 Million |
| 2021 | -18.27% | -704.48% | 0.02x | 1.14x | $-10.11 Million |
| 2022 | -40.31% | -5986.91% | 0.01x | 1.15x | $-28.63 Million |
| 2023 | -219.65% | 0.00% | 0.00x | 1.32x | $-33.65 Million |
| 2024 | -88.58% | 0.00% | 0.00x | 1.58x | $-17.24 Million |
| 2025 | -1.28% | -2.36% | 0.36x | 1.50x | $-3.26 Million |
| 2026 | -0.05% | -1145.66% | 0.00x | 1.17x | $-2.47 Billion |
Industry Comparison
This section compares Neuphoria Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neuphoria Therapeutics Inc (NEUP) | $24.60 Million | 0.00% | 0.17x | $16.18 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also deve… Read more